ATXS
Price
$5.52
Change
+$0.12 (+2.22%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
304.74M
35 days until earnings call
CPRX
Price
$24.46
Change
+$0.55 (+2.30%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
2.97B
34 days until earnings call
Ad is loading...

ATXS vs CPRX

Header iconATXS vs CPRX Comparison
Open Charts ATXS vs CPRXBanner chart's image
Astria Therapeutics
Price$5.52
Change+$0.12 (+2.22%)
Volume$2.21K
Capitalization304.74M
Catalyst Pharmaceuticals
Price$24.46
Change+$0.55 (+2.30%)
Volume$11.56K
Capitalization2.97B
ATXS vs CPRX Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CPRX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and CPRX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ATXS: $5.40 vs. CPRX: $23.92)
Brand notoriety: ATXS and CPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 154% vs. CPRX: 102%
Market capitalization -- ATXS: $304.74M vs. CPRX: $2.97B
ATXS [@Biotechnology] is valued at $304.74M. CPRX’s [@Biotechnology] market capitalization is $2.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCPRX’s FA Score has 2 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, CPRX is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while CPRX’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • CPRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ATXS and CPRX are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -13.60% price change this week, while CPRX (@Biotechnology) price change was -7.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

ATXS is expected to report earnings on May 08, 2025.

CPRX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($2.97B) has a higher market cap than ATXS($305M). CPRX YTD gains are higher at: 14.614 vs. ATXS (-39.597). CPRX has higher annual earnings (EBITDA): 233M vs. ATXS (-111.56M). CPRX has more cash in the bank: 518M vs. ATXS (328M). CPRX has less debt than ATXS: CPRX (3.19M) vs ATXS (5.35M). CPRX has higher revenues than ATXS: CPRX (492M) vs ATXS (0).
ATXSCPRXATXS / CPRX
Capitalization305M2.97B10%
EBITDA-111.56M233M-48%
Gain YTD-39.59714.614-271%
P/E RatioN/A18.67-
Revenue0492M-
Total Cash328M518M63%
Total Debt5.35M3.19M168%
FUNDAMENTALS RATINGS
ATXS vs CPRX: Fundamental Ratings
ATXS
CPRX
OUTLOOK RATING
1..100
8118
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
9733
PRICE GROWTH RATING
1..100
9240
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (63) in the Biotechnology industry is in the same range as CPRX (67) in the Pharmaceuticals Other industry. This means that ATXS’s stock grew similarly to CPRX’s over the last 12 months.

CPRX's Profit vs Risk Rating (13) in the Pharmaceuticals Other industry is significantly better than the same rating for ATXS (100) in the Biotechnology industry. This means that CPRX’s stock grew significantly faster than ATXS’s over the last 12 months.

CPRX's SMR Rating (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATXS (97) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CPRX's Price Growth Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATXS (92) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CPRX's P/E Growth Rating (79) in the Pharmaceuticals Other industry is in the same range as ATXS (100) in the Biotechnology industry. This means that CPRX’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCPRX
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OAYBX36.100.06
+0.17%
Oakmark Equity and Income Advisor
HHDFX34.93N/A
N/A
Hamlin High Dividend Equity Instl
RYEUX111.23N/A
N/A
Rydex Europe 1.25x Strategy H
CREEX9.91N/A
N/A
Columbia Real Estate Equity Inst
JEEIX15.92N/A
N/A
JHancock Infrastructure I

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.12%
KYMR - ATXS
49%
Loosely correlated
-7.80%
DNLI - ATXS
48%
Loosely correlated
-9.60%
TRDA - ATXS
48%
Loosely correlated
-3.10%
ABOS - ATXS
47%
Loosely correlated
-2.27%
IMNM - ATXS
46%
Loosely correlated
-6.98%
More

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with SANA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-1.36%
SANA - CPRX
45%
Loosely correlated
-10.71%
VIR - CPRX
39%
Loosely correlated
-4.63%
CRNX - CPRX
36%
Loosely correlated
-8.71%
ATXS - CPRX
35%
Loosely correlated
+1.12%
CMPX - CPRX
35%
Loosely correlated
+17.89%
More